Lates News

In early trading on Friday, the Dow component Johnson & Johnson rose 1%. Recently, Johnson & Johnson announced that it has submitted an application to the European Medicines Agency seeking approval for the marketing of Icotrokinra, an investigational once-daily oral peptide therapy developed in collaboration with Protagonist. It is intended for the treatment of adults and pediatric patients aged 12 and above with moderate to severe plaque psoriasis. The experimental psoriasis drug is said to show potential superiority over AbbVie's therapy.